Edition:
United States

Aspen Pharmacare Holdings Ltd (APNJ.J)

APNJ.J on Johannesburg Stock Exchange

24,580.00ZAc
25 May 2018
Change (% chg)

316.00 (+1.30%)
Prev Close
24,264.00
Open
24,300.00
Day's High
24,708.00
Day's Low
23,876.00
Volume
1,171,146
Avg. Vol
1,390,026
52-wk High
32,750.00
52-wk Low
22,987.00

Latest Key Developments (Source: Significant Developments)

Aspen Pharmacare Says HY ‍Normalised HEPS Increased By 26 Pct
Thursday, 8 Mar 2018 12:06am EST 

March 8 (Reuters) - Aspen Pharmacare Holdings Ltd ::‍NORMALISED HEADLINE EARNINGS PER SHARE INCREASED BY 26% TO 872 CENTS FOR SIX MONTHS ENDED 31 DECEMBER 2017​.‍HY REVENUE GENERATED BY GROUP GREW 11% TO R21,9 BILLION​.‍PERFORMANCE IN SECOND HALF WILL BENEFIT FROM ADDITIONAL RIGHTS TO AZ ANAESTHETICS FOR FULL SIX MONTHS​.‍ANTICIPATED H2 OPERATING CASH FLOWS WILL REMAIN STRONG; CONVERSION RATE OF 100% OF OPERATING PROFITS IS TARGETED FOR FULL FY.  Full Article

Aspen Expects HY HEPS Between 820.4 To 846.0 Cents Per Share​
Thursday, 15 Feb 2018 01:00am EST 

Feb 15 (Reuters) - Aspen Pharmacare Holdings Ltd ::EXPECTS HY HEADLINE EARNINGS PER TO IMPROVE 28% TO 32% BETWEEN 820.4 TO 846.0 CENTS PER SHARE​.  Full Article

Aspen Pharmacare Receives Approval For Registration Of Alula In China​
Monday, 15 Jan 2018 02:00am EST 

Jan 15 (Reuters) - Aspen Pharmacare Holdings Ltd ::‍ASPEN RECEIVES APPROVAL FOR REGISTRATION OF ALULA IN CHINA​.  Full Article

Aspen Pharmacare Says Has Had No Contact With Viceroy Research
Tuesday, 9 Jan 2018 07:54am EST 

Jan 9 (Reuters) - Aspen Pharmacare Holdings Ltd ::HAS HAD NO CONTACT WITH VICEROY RESEARCH AND, AS SUCH, IS UNABLE TO CONFIRM THAT SPECULATION IS CORRECT.IS NOT AWARE OF ANY INFORMATION OF A PRICE SENSITIVE NATURE THAT REQUIRES COMMUNICATION TO SHAREHOLDERS​.  Full Article

Mylan And Aspen Announce Launch Of Generic Busulfex Injection
Monday, 4 Dec 2017 07:30am EST 

Dec 4 (Reuters) - Mylan Nv ::MYLAN AND ASPEN ANNOUNCE LAUNCH OF GENERIC BUSULFEX® INJECTION.MYLAN NV - ‍ANNOUNCED U.S. LAUNCH OF MYLERAN INJECTION, 60 MG/10 ML SINGLE-DOSE VIAL, A GENERIC VERSION OF OTSUKA PHARMACEUTICAL'S BUSULFEX INJECTION​.  Full Article

Aspen Pharmacare says ‍UK CMA opens investigation against company
Friday, 13 Oct 2017 11:00am EDT 

Oct 13 (Reuters) - Aspen Pharmacare Holdings Ltd :‍UK COMPETITION AND MARKETS AUTHORITY HAS OPENED AN INVESTIGATION AGAINST ASPEN​.‍INVESTIGATION INTO ANTI-COMPETITIVE CONDUCT ON SUPPLY OF FLUDROCORTISONE ACETATE 0.1 MG TABLETS, DEXAMETHASONE 2 MG TABLETS IN UK​.‍INVESTIGATION IS AT AN EARLY, INFORMATION-GATHERING STAGE.CMA CONFIRMED THAT, AT THIS TIME, IT HAS NOT REACHED ANY CONCLUSION ON WHETHER COMPETITION LAW HAS BEEN INFRINGED​.‍ASPEN IS NOT CURRENTLY IN A POSITION TO COMMENT ON INVESTIGATION​.  Full Article

Aspen Pharmacare Holdings ‍welcomes SA Competition Commission’s decision not to refer complaint about Aspen
Wednesday, 4 Oct 2017 08:49am EDT 

Oct 4 (Reuters) - ASPEN PHARMACARE HOLDINGS LTD ::‍WELCOMES SOUTH AFRICAN COMPETITION COMMISSION'S DECISION TO DROP ITS INVESTIGATION OF ASPEN FOR SUSPECTED ABUSE OF DOMINANCE AND EXCESSIVE PRICING.  Full Article

South Africa's Competition Commission to drop investigation against Aspen
Wednesday, 4 Oct 2017 08:25am EDT 

Oct 4 (Reuters) - South Africa's Competition Commission::DECIDED TO DROP INVESTIGATION AGAINST ASPEN, EQUITY PRIVATE LTD BECAUSE EXCESSIVE PRICING CASE CANNOT BE SUSTAINED.DECIDED TO DROP INVESTIGATION AGAINST ASPEN, EQUITY PRIVATE LTD BECAUSE EXCESSIVE PRICING CASE CANNOT BE SUSTAINED.COMMISSION CONTINUES TO INVESTIGATE THE COMPLAINTS INITIATED AGAINST ROCHE, GENENTECH AND PFIZER.FOR ASPEN, INVESTIGATION REVEALED REVENUES ATTRIBUTABLE TO MYLERAN, ALKERAN, LEUKERAN ARE VERY LOW.IN RESPECT OF EQUITY, PROBE REVEALED THAT THE DRUG, XALKORI CRIZOTINIB (XALKORI), IS NOT YET REGISTERED IN SOUTH AFRICA.  Full Article

Aspen Pharmacare Holdings posts FY revenue 41,2 bln rand
Thursday, 14 Sep 2017 02:00am EDT 

Sept 14 (Reuters) - ASPEN PHARMACARE HOLDINGS LTD :FY REVENUE BY 16% TO 41,2 BILLION RAND.RAISED NORMALISED HEADLINE EARNINGS PER SHARE ("NHEPS") BY 16% TO 1 463 CENTS IN YEAR ENDED 30 JUNE 2017..HAS DECLARED A GROSS DIVIDEND, WHICH IS PAID FROM INCOME RESERVES, OF 287 CENTS PER ORDINARY SHARE TO SHAREHOLDERS.  Full Article

Aspen Pharmacare sees full-year NHEPS up 13 pct-18 pct
Wednesday, 30 Aug 2017 08:00am EDT 

Aug 30 (Reuters) - Aspen Pharmacare Holdings Ltd ::‍SEES FY NEHPS AT 1428.0 CENTS PER SHARE TO 1491.2 CENTS PER SHARE, UP 13 PERCENT - 18 PERCENT.SEES HEPS UP 43 PCT TO 48 PCT TO 1271.3 CENTS PER SHARE TO 1315.7 CENTS PER SHARE IN YEAR TO JUNE 30, 2017​​.‍SIGNIFICANT INCREASE IN HEADLINE EARNINGS PER SHARE IS ATTRIBUTABLE TO DEVALUATION OF ASPEN'S VENEZUELAN BUSINESS IN PRIOR YEAR​.  Full Article

South African drugmaker Aspen secures 3.4 billion euro credit line

JOHANNESBURG, May 17 Aspen Pharmacare, Africa's biggest generic drugmaker, said on Thursday it had secured a 3.4 billion euro ($4 billion) credit facility for refinancing debt at three of its subsidiaries.